Justice Department asks Supremes to weigh health law; Novartis launches Votubia in U.K.;

@FiercePharma: Pfizer tells Indian hand-wringers that drug-price controls mean M&A won't touch off runaway price hikes $PFE #pharma. News | Follow @FiercePharma

> The Obama administration has asked the Supreme Court to review its healthcare reform law in a sooner-than-expected move that could yield a decision by June. News

> Novartis ($NVS) has launched Votubia--its everolimus brand aimed at a type of benign brain tumors--in the U.K. after conditional approval from the European Medicines Agency. Item

> A U.S. judge has dismissed Sandoz's antitrust claims against Bayer, saying the Novartis generics unit failed to show Bayer monopolized the U.S. oral contraceptive market. Article

> Questcor Pharmaceuticals ($QCOR) was up more than 9% yesterday after preliminary sales data for its drug Acthar showed an increase of 13% over the second quarter and 160% year-over-year. Report

> Prescriptions for ADHD drugs such as Ritalin and Adderall continue to rise, but at a slower pace than in the past. Story

Biotech News

@FierceBiotech: Proximagen polishes its CNS rep with $16M Lundbeck deal. News | Follow @FierceBiotech

@RyanMFierce: Which women in biotech inspire you? Please tell us here @FierceBiotech: Item | Follow @RyanMFierce

@MaureenFierce: U.S. economic woes "leading to risky Rx practices." People skimping on meds, MD visits. Piece | Follow @MaureenFierce

> Open-source R&D advocates prep $150M cancer drug project. News 

> Which women in biotech inspire you? Article

> Proximagen polishes its CNS rep with $16M Lundbeck deal. Story

Vaccines News

> Gardasil bests Cervarix in cost effectiveness battle. News 

> Vaccine could reduce HIV to 'minor infection.' Report 

> Vaccines critical for controlling chronic diseases. Item 

> Prospective Alzheimer's vax homes in on amyloid delivery. News 

> Agenus encouraged by early HerpV results. Report 

 Manufacturing News

> GSK planning off-grid move for savings. Story 

> Chinese API maker gets stern FDA warning over cross-contamination. Article

> The downside of downsizing: playing it safe. News 

> Google AdWords ban keeps drug savings from U.S. poor. Report 

> Congress gets started on drug-takeback program. Item 

> Lean manufacturing lessons from Human Genome Sciences. Story

And Finally... New evidence that diabetes is somehow linked to colon cancer. Item

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.